Model-informed cefepime dosing in children changed half the regimens

Design

Prospective observational service evaluation

Population

19 patients (20 consultations) at a quaternary children's hospital

Primary outcome

Turnaround time and change in dosing regimen

Effect

50% new dosing strategy, 40% continued; median turnaround 27.8 hours

A US quaternary children's hospital described the first year of a consultation service that used drug levels and population pharmacokinetic models to individualise cefepime dosing. Nineteen patients, median age 2.7 years, received 20 consultations; half were on extracorporeal support such as dialysis or ECMO.

In 40% of consultations the advice was to continue the current regimen, and in 50% a new dose, frequency or infusion duration was recommended. One patient was switched to meropenem because of concern about neurotoxicity. Recommendations took a median of 28 hours from request, held back by logistics, communication and training gaps.

This is a small feasibility report, not an outcome study. Its value is in showing where standard cefepime doses go wrong: extracorporeal circuits and changing renal function make exposure unpredictable in exactly the sickest children.

• Expect unpredictable cefepime exposure in children on dialysis or ECMO.
• Where drug-level measurement is available, consider it for critically ill children on cefepime.
• Extended or continuous infusions are one way to improve target attainment.
• Turnaround time limits usefulness; agree the sampling and reporting pathway in advance.

Why it matters

Standard dosing assumes a stable patient, and half the children here needed a different regimen.

Don't overread it

Nineteen patients at one centre; no clinical outcomes were compared.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.